Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenecteplase IV thrombolysis in mild ischemic stroke (real-world, multicenter cohort)
ChiCTR2500102527Phase 4Recruiting
- Sponsor
- Xiangyang No.1 People's Hospital
- Start
- May 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of tenecteplase in ischemic stroke and cerebrovascular disease (2 arms), sponsored by Xiangyang No.1 People's Hospital. Primary endpoint: 90-day modified Rankin Scale score 0–1. Started May 2025; status: recruiting.
02
Drugs
tenecteplase
03
Conditions
ischemic strokecerebrovascular disease
Beyond the preview
Go deeper on ChiCTR2500102527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102527.